Kristina E N Clark,Christopher P Denton
Kristina E N Clark
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis [0.03%]
glucagon-like peptide-1受体激动剂的使用与系统性红斑狼疮和狼疮性肾炎患者不良心脏及肾脏结局的风险关系
April Jorge,Aakash V Patel,Baijun Zhou et al.
April Jorge et al.
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardioprotective and kidney-protective benefits among patients with type 2 diabetes (T2D). We sought to determine whether GLP-1RA use improves cardiovasc...
Monica Guma,Robert Terkeltaub
Monica Guma
Long-term remission with ustekinumab in a patient with PAPA syndrome suggests the importance of IL-12/IL-23 cytokines in PSTPIP1-associated inflammatory diseases [0.03%]
长期使用乌司奴单抗治疗PAPA综合征患者获得缓解，提示IL-12/IL-23细胞因子在与PSTPIP1相关的炎性疾病中的重要作用
Nico Wittmann,Dominik Nell,Magdalena Mohs et al.
Nico Wittmann et al.
Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome - an international multicenter study [0.03%]
阿那白滞素与卡那利珠单抗治疗VEXAS综合征患者的疗效和安全性比较——一项国际多中心研究
Tali Eviatar,Dafne Capelusnik,Corrado Campochiaro et al.
Tali Eviatar et al.
Objectives: The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. ...
Effect of time to start of biologic therapy on treatment response in childhood arthritis: Results from the UCAN CAN-DU study [0.03%]
加拿大儿童关节炎研究中生物制剂起始时间对治疗反应的影响：UCAN CAN-DU 研究结果
Jelleke B de Jonge,Sytze de Roock,Dieneke Schonenberg-Meinema et al.
Jelleke B de Jonge et al.
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients with Eosinophilic Granulomatosis with Polyangiitis [0.03%]
Benralizumab和Mepolizumab对好柳酸性肉芽肿伴血管炎患者口服糖皮质激素使用的影响
Parameswaran K Nair,Bernhard Hellmich,Arnaud Bourdin et al.
Parameswaran K Nair et al.
Objective: The Phase 3 MANDARA study demonstrated non-inferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab-treated patients ...
Familial Aggregation in Psoriatic Arthritis: Phenotypic Differences in Patients With and Without a Family History of Psoriatic Disease [0.03%]
银屑病关节炎的家族聚集性：有和无银屑病家族史患者的表型差异
Catherine Howe,Jiyuan Hu,Weixi Chen et al.
Catherine Howe et al.
Objective: Although up to 45% of patients with psoriatic arthritis (PsA) have a family history of psoriatic disease, it is unclear whether this family history contributes to a distinct PsA phenotype and/or the timing of d...
Autoantibody Response Toward Chromatin in Patients With Juvenile Idiopathic Arthritis [0.03%]
儿童特发性关节炎患者的抗核抗体反应
Viola Pitkänen,Terhi Remes-Pakarinen,Paula Vähäsalo et al.
Viola Pitkänen et al.
Objective: Patients with juvenile idiopathic arthritis (JIA) frequently exhibit antinuclear antibodies (ANAs), but the specific antigen target recognized by them and the presence of additional autoantibody specificities i...
Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden [0.03%]
广泛的UBA1突变负荷下VEXAS综合征的临床表现
Meghan Anderson,Defne Ercelen,Ashley Richardson et al.
Meghan Anderson et al.
Objective: Vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a progressive systemic autoinflammatory disorder caused by somatic variants in UBA1 in blood. Previous analyses ...